AstraZeneca tumbles as heart drug trial misses main efficacy goal
Seeking Alpha ·
AstraZeneca ( AZN ) shares tumbled nearly 10% in London after a late-stage trial for an experimental heart disease failed to meet its target. The CARDIO-TTRansform Phase III trial for AstraZeneca and Ionis’ ( IONS ) Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not
DYAX Investor Sentiment
Bullish (Long) 56% · Bearish (Short) 44%
432 participants
Related News
- Vision Marine jumps 23% on $13.1M Florida property monetization
- Earnings Snapshot: Pepsico Q2 revenue tops estimates, but core EPS and organic growth drag; FY26 outlook affirmed
- Airbnb buys first New York office building for $81.5M: WSJ
- ExxonMobil and partners commit $1bn to launch Usan Infill Project
- PepsiCo in Charts: Seasonal Q/Q growth seen across all business segments in Q2
- U.S. chip stocks rebound, tracking China semiconductor rally